

COMPLETION OF TEST AND LEARN PROGRAM WITH TIER 1 US RETAILER

October 20 2017, Melbourne, Australia

Nasal respiratory technology company Rhinomed Limited (ASX:RNO) advises that it has completed a 'Test and Learn' trial program in 100 stores of a Tier 1 American pharmacy chain.

Initially announced on July 22, 2016, the trial ran in approximately 100 pharmacy stores as part of an in-store program designed for an initial six month period. The trial began in August 2016 and has now been completed.

The objective of the trial was to obtain data about consumers who shop within the sleep category in pharmacy. Following the completion of the trial, Rhinomed and the retailer have begun interrogation of the data captured. Further discussions are underway regarding ranging in store as part of the pharmacy's annual product review process that takes place over the coming months.

The company will continue to update investors on the progress of its US business as these deals are completed.

Mute is developed from an internal nasal technology platform that is designed to structurally support the nasal valve, increase airflow and aid in the reduction of snoring for those one in four people who suffer from some form of nasal obstruction.

The completion of this trial with this Tier 1 US retailer follows the recently announced expansion to over 4300 stores in the Walgreens network in the USA. The company can advise that Mute is now stocked on the shelves of these Walgreens stores. Mute is available in the USA, Canada, the UK and Australia.

Media Enquiries

+61 (03) 8416 0900

mjohnson@rhinomed.global

Follow us on Twitter @rhinomedceo and @theturbinecom

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global